Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04645342 · ClinicalTrials.gov registry record · NA
Wire Instrumentation Using Radiofrequency Energy to Impact Transseptal Efficiency
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 75
- Enrollment target
NCT04645342 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 75 participants.
The verdict
NCT04645342, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 75 participants
- Enrollment target
Study Summary
This is a randomized controlled trial examining whether Baylis's Versacross RF wire versus the conventional Baylis RF needle is better at puncturing through a thin wall in the heart (called "transseptal puncture") as measured by time to successful transseptal puncture, during cardiac ablation procedures.
Interventions
- DEVICE Baylis Versacross RF wire
- DEVICE Baylis RF needle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2020-11-30 |
| Est. Completion | 2022-02-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04645342
The ClinicalTrials.gov registry entry for NCT04645342 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Baylis Versacross RF wire is the first listed.
NCT04645342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04645342 about?
NCT04645342 is a clinical study titled "Wire Instrumentation Using Radiofrequency Energy to Impact Transseptal Efficiency". This is a randomized controlled trial examining whether Baylis's Versacross RF wire versus the conventional Baylis RF needle is better at puncturing through a thin wall in the heart (called "transseptal puncture") as measured by time to successful transseptal puncture, during cardiac ablation proced...
What is the current status of trial NCT04645342?
This trial is currently completed. It is a NA study. The enrollment target is 75 participants. The study started on 2020-11-30. Estimated completion is 2022-02-02.
What interventions are being tested in trial NCT04645342?
The interventions under investigation include: Baylis Versacross RF wire (DEVICE), Baylis RF needle (DEVICE).
Who is sponsoring clinical trial NCT04645342?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.